Physician survey on monitoring of patients treated with quetiapine
Study identifier:D1443C00127
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Assessment of physician behavior regarding metabolic monitoring of patients treated with SEROQUEL® (quetiapine fumarate) Tablets and SEROQUEL® (quetiapine fumarate) Extended Release Tablets in selected countries in the EU
Medical condition
schizophrenia
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
0
Study type
Observational
Age
N/A
Date
Study Start Date: 01 Jun 2013
Primary Completion Date: 01 Sept 2013
Study Completion Date: 01 Sept 2013
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Oct 2015 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Germany A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
| United Kingdom A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
| Spain A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
| Hungary A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
| Netherlands A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
| Sweden A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
| Romania A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
| Italy A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. | - |
Contacts
Investigators
Principal Investigator
Robert S Brody
AZ
